Papers associated with grin2a

???displayGene.coCitedPapers???

???pagination.result.count???

???pagination.result.page??? 1 2 3 4 ???pagination.result.next???

Sort Newest To Oldest

Sort Oldest To Newest

	Advancements in the use of xenopus oocytes for modelling neurological disease for novel drug discovery., O'Connor EC, Kambara K, Bertrand D., Expert Opin Drug Discov. February 1, 2024; 19 (2): 173-187.
	A convergent molecular network underlying autism and congenital heart disease., Rosenthal SB, Willsey HR, Xu Y, Xu Y, Mei Y, Dea J, Wang S, Curtis C, Sempou E, Khokha MK, Chi NC, Willsey AJ, Fisch KM, Ideker T., Cell Syst. November 17, 2021; 12 (11): 1094-1107.e6.
	Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders., Tang W, Liu D, Traynelis SF, Yuan H., Neuropharmacology. October 15, 2020; 177 108247.
	Subunit-specific effects of poricoic acid A on NMDA receptors., Lee J, Kim C, Yeom HD, Nguyen KVA, Eom S, Lee S, Jung JH, Lee JH, Kim SH, Kim IK, Lee JH, Lee JH., Pharmacol Rep. April 1, 2020; 72 (2): 472-480.
	De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases., Li J, Zhang J, Tang W, Mizu RK, Kusumoto H, XiangWei W, Xu Y, Chen W, Amin JB, Hu C, Kannan V, Keller SR, Wilcox WR, Lemke JR, Myers SJ, Swanger SA, Wollmuth LP, Petrovski S, Traynelis SF, Yuan H., Hum Mutat. December 1, 2019; 40 (12): 2393-2413.
	A novel missense mutation in GRIN2A causes a nonepileptic neurodevelopmental disorder., Fernández-Marmiesse A, Kusumoto H, Rekarte S, Roca I, Zhang J, Myers SJ, Traynelis SF, Couce ML, Gutierrez-Solana L, Yuan H., Mov Disord. July 1, 2018; 33 (6): 992-999.
	An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups., Perszyk R, Katzman BM, Kusumoto H, Kell SA, Epplin MP, Tahirovic YA, Moore RL, Menaldino D, Burger P, Liotta DC, Traynelis SF., Elife. May 24, 2018; 7
	All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class., Castillo-Gómez E, Oliveira B, Tapken D, Bertrand S, Klein-Schmidt C, Pan H, Zafeiriou P, Steiner J, Jurek B, Trippe R, Prüss H, Zimmermann WH, Bertrand D, Ehrenreich H, Hollmann M., Mol Psychiatry. December 1, 2017; 22 (12): 1776-1784.
	Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology., Ogden KK, Chen W, Swanger SA, McDaniel MJ, Fan LZ, Hu C, Tankovic A, Kusumoto H, Kosobucki GJ, Schulien AJ, Su Z, Pecha J, Bhattacharya S, Petrovski S, Cohen AE, Aizenman E, Traynelis SF, Yuan H., PLoS Genet. January 17, 2017; 13 (1): e1006536.
	MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit., Volkmann RA, Fanger CM, Anderson DR, Sirivolu VR, Paschetto K, Gordon E, Virginio C, Gleyzes M, Buisson B, Steidl E, Mierau SB, Fagiolini M, Menniti FS., PLoS One. January 1, 2016; 11 (2): e0148129.
	Potencies and unblocking kinetic properties of antagonists at recombinant human NMDA receptors in a Xenopus oocytes model., Heusler P, Tourette A, Cussac D., Naunyn Schmiedebergs Arch Pharmacol. May 1, 2015; 388 (5): 509-16.
	Effect of a GRIN2A de novo mutation associated with epilepsy and intellectual disability on NMDA receptor currents and Mg(2+) block in cultured primary cortical neurons., Marwick K, Skehel P, Hardingham G, Wyllie D., Lancet. February 26, 2015; 385 Suppl 1 S65.
	GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine., Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR, Markello T, Golas G, Simeonov DR, Holloman C, Tankovic A, Karamchandani MM, Schreiber JM, Mullikin JC, PhD for the NISC Comparative Sequencing Program, Tifft CJ, Toro C, Boerkoel CF, Traynelis SF, Gahl WA., Ann Clin Transl Neurol. March 1, 2014; 1 (3): 190-198.
	Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes., Lemke JR, Lal D, Reinthaler EM, Steiner I, Nothnagel M, Alber M, Geider K, Laube B, Schwake M, Finsterwalder K, Franke A, Schilhabel M, Jähn JA, Muhle H, Boor R, Van Paesschen W, Caraballo R, Fejerman N, Weckhuysen S, De Jonghe P, Larsen J, Møller RS, Hjalgrim H, Addis L, Tang S, Hughes E, Pal DK, Veri K, Vaher U, Talvik T, Dimova P, Guerrero López R, Serratosa JM, Linnankivi T, Lehesjoki AE, Ruf S, Wolff M, Buerki S, Wohlrab G, Kroell J, Datta AN, Fiedler B, Kurlemann G, Kluger G, Hahn A, Haberlandt DE, Kutzer C, Sperner J, Becker F, Weber YG, Feucht M, Steinböck H, Neophythou B, Ronen GM, Gruber-Sedlmayr U, Geldner J, Harvey RJ, Hoffmann P, Herms S, Altmüller J, Toliat MR, Thiele H, Nürnberg P, Wilhelm C, Stephani U, Helbig I, Lerche H, Zimprich F, Neubauer BA, Biskup S, von Spiczak S., Nat Genet. September 1, 2013; 45 (9): 1067-72.
	PI 3-kinase and PKCζ mediate insulin-induced potentiation of NMDA receptor currents in Xenopus oocytes., Jones ML, Liao GY, Malecki R, Li M, Salazar NM, Leonard JP., Dev Biol. January 13, 2012; 1432 7-14.
	PSD-95 interacts with NBCn1 and enhances channel-like activity without affecting Na/HCO(3) cotransport., Lee S, Yang HS, Kim E, Ju EJ, Kwon MH, Dudley RK, Smith Y, Yun CC, Choi I., Cell Physiol Biochem. January 1, 2012; 30 (6): 1444-55.
	A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons., Kostakis E, Jang MK, Russek SJ, Gibbs TT, Farb DH., J Neurochem. November 1, 2011; 119 (3): 486-96.
	Zinc alleviates pain through high-affinity binding to the NMDA receptor NR2A subunit., Nozaki C, Vergnano AM, Filliol D, Ouagazzal AM, Le Goff A, Carvalho S, Reiss D, Gaveriaux-Ruff C, Neyton J, Paoletti P, Kieffer BL., Nat Neurosci. July 3, 2011; 14 (8): 1017-22.
	Amyloid β peptide oligomers directly activate NMDA receptors., Texidó L, Martín-Satué M, Alberdi E, Solsona C, Matute C., Cell Calcium. March 1, 2011; 49 (3): 184-90.
	Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists., Mosley CA, Acker TM, Hansen KB, Mullasseril P, Andersen KT, Le P, Vellano KM, Bräuner-Osborne H, Liotta DC, Traynelis SF., J Med Chem. August 12, 2010; 53 (15): 5476-90.
	Characterization of conantokin Rl-A: molecular phylogeny as structure/function study., Gowd KH, Watkins M, Twede VD, Bulaj GW, Olivera BM., J Pept Sci. August 1, 2010; 16 (8): 375-82.
	4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues., Lolli ML, Giordano C, Pickering DS, Rolando B, Hansen KB, Foti A, Contreras-Sanz A, Amir A, Fruttero R, Gasco A, Nielsen B, Johansen TN., J Med Chem. May 27, 2010; 53 (10): 4110-8.
	N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse., Costa BM, Feng B, Tsintsadze TS, Morley RM, Irvine MW, Tsintsadze V, Lozovaya NA, Jane DE, Monaghan DT., J Pharmacol Exp Ther. November 1, 2009; 331 (2): 618-26.
	Control of NMDA receptor function by the NR2 subunit amino-terminal domain., Yuan H, Hansen KB, Vance KM, Ogden KK, Traynelis SF., J Neurosci. September 30, 2009; 29 (39): 12045-58.
	Cloning and Phylogenetic Analysis of NMDA Receptor Subunits NR1, NR2A and NR2B in Xenopus laevis Tadpoles., Ewald RC, Cline HT., Front Mol Neurosci. September 11, 2009; 2 4.
	Presynaptic NR2A-containing NMDA receptors implement a high-pass filter synaptic plasticity rule., Bidoret C, Ayon A, Barbour B, Casado M., Proc Natl Acad Sci U S A. August 18, 2009; 106 (33): 14126-31.
	The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors., Yuan H, Vance KM, Junge CE, Geballe MT, Snyder JP, Hepler JR, Yepes M, Low CM, Traynelis SF., J Biol Chem. May 8, 2009; 284 (19): 12862-73.
	Pharmacological characterization of recombinant NR1/NR2A NMDA receptors with truncated and deleted carboxy termini expressed in Xenopus laevis oocytes., Puddifoot CA, Chen PE, Schoepfer R, Wyllie DJ., Br J Pharmacol. February 1, 2009; 156 (3): 509-18.
	Stereocontrolled synthesis and pharmacological evaluation of azetidine-2,3-dicarboxylic acids at NMDA receptors., Sivaprakasam M, Hansen KB, David O, Nielsen B, Traynelis SF, Clausen RP, Couty F, Bunch L., ChemMedChem. January 1, 2009; 4 (1): 110-7.
	Molecular determinants of multiple effects of nickel on NMDA receptor channels., Gavazzo P, Guida P, Zanardi I, Marchetti C., Neurotox Res. January 1, 2009; 15 (1): 38-48.
	Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N-methyl-D-aspartate receptor., Han X, Tomitori H, Mizuno S, Higashi K, Füll C, Fukiwake T, Terui Y, Leewanich P, Nishimura K, Toida T, Williams K, Kashiwagi K, Igarashi K., J Neurochem. December 1, 2008; 107 (6): 1566-77.
	Differential effect of high pressure on NMDA receptor currents in Xenopus laevis oocytes., Mor A, Levy S, Hollmann M, Gerossman Y., Diving Hyperb Med. December 1, 2008; 38 (4): 194-6.
	Anesthetic-like modulation of receptor function by surfactants: a test of the interfacial theory of anesthesia., Yang L, Sonner JM., Anesth Analg. September 1, 2008; 107 (3): 868-74.
	Differential effects of linear and cyclic polyamines on NMDA receptor activities., Masuko T, Miyake M, Kusama-Eguchi K, Koike T, Kimura E, Kizawa Y, Kashiwagi K, Igarashi K, Kusama T., Neurochem Int. July 1, 2008; 53 (1-2): 38-44.
	Memantine does not show intracellular block of the NMDA receptor channel., Parsons CG, Gilling KE, Jatzke C., Eur J Pharmacol. June 10, 2008; 587 (1-3): 99-103.
	Roles of NR2A and NR2B in the development of dendritic arbor morphology in vivo., Ewald RC, Van Keuren-Jensen KR, Aizenman CD, Cline HT., J Neurosci. January 23, 2008; 28 (4): 850-61.
	Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition., Gielen M, Le Goff A, Stroebel D, Johnson JW, Neyton J, Paoletti P., Neuron. January 10, 2008; 57 (1): 80-93.
	Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes., Wrighton DC, Baker EJ, Chen PE, Wyllie DJ., J Physiol. January 1, 2008; 586 (1): 211-25.
	Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes., Chen PE, Geballe MT, Katz E, Erreger K, Livesey MR, O'Toole KK, Le P, Lee CJ, Lee CJ, Snyder JP, Traynelis SF, Wyllie DJ., J Physiol. January 1, 2008; 586 (1): 227-45.
	The N-terminal domains of both NR1 and NR2 subunits determine allosteric Zn2+ inhibition and glycine affinity of N-methyl-D-aspartate receptors., Madry C, Mesic I, Betz H, Laube B., Mol Pharmacol. December 1, 2007; 72 (6): 1535-44.
	Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors., Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ, Lee CJ, Yuan H, Le P, Lyuboslavsky PN, Micale N, Jørgensen L, Clausen RP, Wyllie DJ, Snyder JP, Traynelis SF., Mol Pharmacol. October 1, 2007; 72 (4): 907-20.
	Anesthetic properties of the ketone bodies beta-hydroxybutyric acid and acetone., Yang L, Zhao J, Milutinovic PS, Brosnan RJ, Eger EI, Sonner JM., Anesth Analg. September 1, 2007; 105 (3): 673-9.
	Anesthetic-like modulation of a gamma-aminobutyric acid type A, strychnine-sensitive glycine, and N-methyl-d-aspartate receptors by coreleased neurotransmitters., Milutinovic PS, Yang L, Cantor RS, Eger EI, Sonner JM., Anesth Analg. August 1, 2007; 105 (2): 386-92.
	Ammonia has anesthetic properties., Brosnan RJ, Yang L, Milutinovic PS, Zhao J, Laster MJ, Eger EI, Sonner JM., Anesth Analg. June 1, 2007; 104 (6): 1430-3, table of contents.
	Subunit-specific contribution of pore-forming domains to NMDA receptor channel structure and gating., Sobolevsky AI, Prodromou ML, Yelshansky MV, Wollmuth LP., J Gen Physiol. June 1, 2007; 129 (6): 509-25.
	Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block., Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Almonte A, Murray E, Mosely C, Barber J, French A, Balster R, Murray TF, Traynelis SF., J Physiol. May 15, 2007; 581 (Pt 1): 107-28.
	Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif., Takahashi H, Shin Y, Cho SJ, Zago WM, Nakamura T, Gu Z, Ma Y, Furukawa H, Liddington R, Zhang D, Tong G, Chen HS, Lipton SA., Neuron. January 4, 2007; 53 (1): 53-64.
	Cyclophane and acyclic cyclophane: novel channel blockers of N-methyl-D-aspartate receptor., Masuko T, Nagaoka H, Miyake M, Metori K, Kizawa Y, Kashiwagi K, Igarashi K, Kusama T., Neurochem Int. January 1, 2007; 50 (2): 443-9.
	PSD-95 and PKC converge in regulating NMDA receptor trafficking and gating., Lin Y, Jover-Mengual T, Wong J, Bennett MV, Zukin RS., Proc Natl Acad Sci U S A. December 26, 2006; 103 (52): 19902-7.
	Mutations within the selectivity filter of the NMDA receptor-channel influence voltage dependent block by 5-hydroxytryptamine., Kloda A, Adams DJ., Br J Pharmacol. September 1, 2006; 149 (2): 163-9.

???pagination.result.page??? 1 2 3 4 ???pagination.result.next???